Current advances in the treatment of neovascular age-related macular degeneration

References

• Augood CA, Vingerling JR, de Jong PT, et al. Prevalence of age-related maculopathy in older Europeans: the European Eye Study (EUREYE). Arch Ophthalmol. 2006;124(4):529–535.
   PubMedGoogle Scholar
• Mitchell P, Smith W, Attebo K, et al. Prevalence of age-related maculopathy in Australia: the Blue Mountains Eye Study. Ophthalmology. 1995;102(10):1450–1460.
   PubMed Web of Science ®Google Scholar
• Klein R, Klein BE, Linton KL. Prevalence of age-related maculopathy: the Beaver Dam Eye Study. Ophthalmology. 1992;99(6):933–943.
   PubMed Web of Science ®Google Scholar
• Resnikoff S, Pascolini D, Etya’ale D, et al. Global data on visual impairment in the year 2002. Bull World Health Organ. 2004;82:844–851.
   PubMed Web of Science ®Google Scholar
• Nowak JZ. Age-related macular degeneration (AMD): pathogenesis and therapy. Pharmacol Rep. 2006;58:353–363.
   PubMed Web of Science ®Google Scholar
• Ghate D, Edelhauser HF. Ocular drug delivery. Expert Opin Drug Deliv. 2006;3:275–287.
   PubMed Web of Science ®Google Scholar
• Kovach JL, Schwartz SG, Flynn HW Jr. Scott IU. Anti-VEGF treatment strategies for wet AMD. J Ophthalmol. 2012;2012:1–7. doi:10.1155/2012/786870.
   Web of Science ®Google Scholar
• Martin DF, Maguire MG, Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group. et al. Ranibizumab and bevacizumab for treatment of age-related macular degeneration: 2-year results. Ophthalmology. 2012;119(7):1388–1398.
   PubMed Web of Science ®Google Scholar
• Bressler NM, Chang TS, Fine JT, et al. Improved vision-related function after ranibizumab vs photodynamic therapy: a randomized clinical trial. Arch Ophthalmol. 2009;127(1):13–21.
   PubMedGoogle Scholar
• Day S, Acquah K, Mruthyunjaya P, et al. Ocular complications after anti-vascular endothelial growth factor therapy in Medicare patients with age-related macular degeneration. Am J Ophthalmol. 2011;152(2):266–272.
   PubMed Web of Science ®Google Scholar
• Michels S, Rosenfeld PJ, Puliafito CA, et al. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twelve-week results of an uncontrolled open-label clinical study. Ophthalmology. 2005;112:1035–1047.
   PubMed Web of Science ®Google Scholar
• Hurwitz HI, Tebbutt NC, Kabbinavar F, et al. Efficacy and safety of bevacizumab in metastatic colorectal cancer: pooled analysis from seven randomized controlled trials. Oncologist. 2013;18(9):1004–1012.
   PubMed Web of Science ®Google Scholar
• Silva-Garcia R, McLellan C, Shaya FS, et al. Long-lasting effects of anti-VEGF/photodynamic combination therapy in the treatment of exudative age-related macular degeneration: a retrospective chart review. Clin Ophthalmol. 2014 Dec;15(8):2529–2532.
   Google Scholar
• Gragoudas ES, Adamis AP, Cunningham ET Jr, et al. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med. 2004;351:2805–2816.
   PubMed Web of Science ®Google Scholar
• Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age related macular degeneration. N Engl J Med. 2006;355:1419–1431.
   PubMed Web of Science ®Google Scholar
• Heier JS, Brown DM, Chong V, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012;119:2537–2548.
   PubMed Web of Science ®Google Scholar
• CATT Research Group, Martin DF, Maguire MG, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011;364(20):1897–1908.
   PubMed Web of Science ®Google Scholar
• Schwartz SG, Flynn HW, Scott IU. Endophthalmitis after intravitreal injections. Expert Opin Pharmacother. 2009;10:2119–2126.
   PubMed Web of Science ®Google Scholar
• Sharma S, Johnson D, Abouammoh M, et al. Rate of serious adverse effects in a series of bevacizumab and ranibizumab injections. Can J Ophthalmol. 2012;47:275–279.
   PubMed Web of Science ®Google Scholar
• Forooghian F, Cukras C, Meyerle CB, et al. Tachyphylaxis after intravitreal bevacizumab for exudative age-related macular degeneration. Retina. 2009;29:723–731.
   PubMed Web of Science ®Google Scholar
• Pershing S, Bakri SJ, Moshfeghi DM. Ocular hypertension and intraocular pressure asymmetry after intravitreal injection of antivascular endothelial growth factor agents. Ophthalmic Surg Lasers Imaging Retina. 2013;44:460–464.
   PubMed Web of Science ®Google Scholar
• Gregori NZ, Flynn HW Jr, Schwartz SG, et al. Current infectious endophthalmitis rates after intravitreal injections of anti-vascular endothelial growth factor agents and outcomes of treatment. Ophthalmic Surg Lasers Imaging Retina. 2015 Jun;46(6):643–648.
   PubMed Web of Science ®Google Scholar
• Lalwani GA, Rosenfeld PJ, Fung AE, et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO study. Am J Ophthalmol. 2009 Jul;148(1):43–58.e1.
   PubMed Web of Science ®Google Scholar
• Fung AT, Kumar N, Vance SK, et al. Pilot study to evaluate the role of high-dose ranibizumab 2.0 mg in the management of neovascular age-related macular degeneration in patients with persistent/recurrent macular fluid <30 days following treatment with intravitreal anti-VEGF therapy (the LAST Study). Eye (Lond). 2012 Sep;26(9):1181–1187.
   PubMed Web of Science ®Google Scholar
• Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group, Martin DF, Maguire MG, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology. 2012 Jul;119(7):1388–1398.
   PubMed Web of Science ®Google Scholar
• Chakravarthy U, Harding SP, Rogers CA, et al. Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. Lancet. 2013 Oct 12;382(9900):1258–1267.
   PubMed Web of Science ®Google Scholar
• Saint-Geniez M, Maharaj AS, Walshe TE, et al. Endogenous VEGF is required for visual function: evidence for a survival role on Muller cells and photoreceptors. PLoS ONE. 2008;3:e3554.
   PubMed Web of Science ®Google Scholar
• Rosenfeld PJ, Shapiro H, Tuomi L, et al. Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials. Ophthalmology. 2011;118:523–530.
   PubMed Web of Science ®Google Scholar
• Grisanti S, Tatar O. The role of vascular endothelial growth factor and other endogenous interplayers in age-related macular degeneration. Prog Retin Eye Res. 2008;27:372–390.
   PubMed Web of Science ®Google Scholar
• Medina C, Santos-Martínez MJ, Radomski A, et al. Nanoparticles: pharmacological and toxicological significance. Br J Pharmacol. 2007;150:552–558.
   PubMed Web of Science ®Google Scholar
• Sahoo SK, Parveen S, Panda JJ. The present and future of nanotechnology in human health care. Nanomedicine. 2007;3:20–31.
   PubMed Web of Science ®Google Scholar
• Gaudana R, Jwala J, Boddu SHS, et al. Recent perspectives in ocular drug delivery. Pharm Res. 2009;26:1197–1216.
   PubMed Web of Science ®Google Scholar
• Sanchez A, Alonso MJ. Nanoparticular carriers for ocular drug delivery. In: Torchilin V, editor. Nanoparticulates as drug carriers, 1-86094-630-5. London: World Scientific-Imperial College Press: 2006. Chapter 27; p. 1–30.
   Google Scholar
• Kauper K, McGovern C, Sherman S, et al. Two-year intraocular delivery of ciliary neurotrophic factor by encapsulated cell technology implants in patients with chronic retinal degenerative diseases. Invest Ophthalmol Vis Sci. 2012;53:7894.
   Web of Science ®Google Scholar
• Chew EY, Clemons TE, Peto T, et al. Ciliary neurotrophic factor for macular telangiectasia type 2: results from a phase 1 safety trial. Am J Ophthalmol. 2015;159(4):659–666.e1. Epub 2014 Dec 19.
   PubMed Web of Science ®Google Scholar
• Gooch N, Burr RM, Holt DJ, et al. Design and in vitro biocompatibility of a novel ocular drug delivery device. J Funct Biomater. 2013;4:14–26.
   PubMedGoogle Scholar
• Loewenstein A. Refillable drug delivery implant providing sustained release anti-VEGF therapy in wet AMD. Miami, FL: Angiogenesis, exudation, and degeneration; 2013.
   Google Scholar
• Saati S, Lo R, Li PY, et al. Mini drug pump for ophthalmic use. Trans Am Ophthalmol Soc. 2009 Dec;107:60–70.
   PubMedGoogle Scholar
• Stevenson CL, Santini JT Jr, Langer R. Reservoir-based drug delivery systems utilizing microtechnology. Adv Drug Deliv Rev. 2012;64:1590–1602.
   PubMed Web of Science ®Google Scholar
• Bakri SJ, Snyder MR, Pulido JS, et al. Six-month stability of bevacizumab (Avastin) binding to vascular endothelial growth factor after withdrawal into a syringe and refrigeration or freezing. Retina. 2006;26:519–2.
   PubMed Web of Science ®Google Scholar
• Maurice D. Review: practical issues in intravitreal drug delivery. J Ocul Pharmacol Ther. 2001;17:393–401.
   PubMed Web of Science ®Google Scholar
• Zaman RT, Gopal A, Starr K, et al. Micro-patterned drug delivery device for light-activated drug release. Laser Surg Med. 2012;44:30–48.
   PubMed Web of Science ®Google Scholar
• Koc A, Onal S, Yenice O, et al. Pars plana vitrectomy and intravitreal liposomal amphotericin B in the treatment of Candida endophthalmitis. Ophthalmic Surg Lasers Imaging. 2010. doi:10.3928/1542887-20100215-35.
   PubMedGoogle Scholar
• Honda M, Asai T, Oku N, et al. Liposomes and nanotechnology in drug development: focus on ocular targets. Int J Nanomedicine. 2013;8:495–503.
   PubMed Web of Science ®Google Scholar
• Honda M, Asai T, Umemoto T, et al. Suppression of choroidal neovascularization by intravitreal injection of liposomal SU5416. Arch Ophthlamol. 2011;129:317–321.
   PubMed Web of Science ®Google Scholar
• Abrishami M, Zarei-Ghanavati S, Souroush D, et al. Preparation, characterization, and in vivo evaluation of nanoliposomes-encapsulated bevacizumab (Avastin) for intravitreal administration. Retina. 2009;29:699–703.
   PubMed Web of Science ®Google Scholar
• Farjo KM, Ma JX. The potential of nanomedicine therapies to treat neovascular disease in the retina. J Angiogenesis Res. 2010;2:21.
   PubMedGoogle Scholar
• Kompella UB, Amrite AC, Pacha Ravi R, et al. Nanomedicines for the back of the eye drug delivery, gene delivery, and imaging. Prog Retin Eye Res. 2013;36:172–198.
   PubMed Web of Science ®Google Scholar
• Carrasquillo KG, Ricker JA, Rigas IK, et al. Controlled delivery of the anti-VEGF aptamer EYE001 with poly(lacticco glycolic)acid microspheres. Invest Ophthalmol Vis Sci. 2003;44(1):290–299.
   Google Scholar
• Shelke NB, Kadam R, Tyagi P, et al. Intravitreal poly(L-lactide) microparticles sustain retinal and choroidal delivery of TG 0054, a hydrophilic drug intended for neovascular diseases. Drug Deliv Transl Res. 2011;1:76–90.
   PubMed Web of Science ®Google Scholar
• Kang Derwent JJ, Mieler WF. Thermoresponsive hydrogels as a new ocular drug delivery platform to the posterior segment of the eye. Trans Am Ophthalmol Soc. 2008;106:206–213.
   PubMedGoogle Scholar
• Wang CH, Hwang YS, Chiang PR, et al. Extended release of bevacizumab by thermosensitive biodegradable and biocompatible hydrogel. Biomacromolecules. 2012;13:40–48.
   PubMed Web of Science ®Google Scholar
• Dugel P. Results of ESBA 1008, a single-chain antibody fragment for the treatment of neovascular AMD. Paper presented at: annual meeting of the American Society of Retina Specialists; 2014 Aug 9–13; San Diego, CA.
   Google Scholar
• Novartis. Positive phase II data highlights benefits of Alcon’s RTH258 for patients with neovascular (wet) age-related macular degeneration. Alcon Web site; cited 2016 Mar 17. Available from: https://www.novartis.com/news/media-releases/positive-phase-ii-data-highlights-benefits-alcons-rth258-patients-neovascular.
   Google Scholar
• Kaiser PK. Anti-VEGF therapy in wet AMD and conbercept development. Presented at: angiogenesis, Exudation, and Degeneration 2014; 2014 Feb 8; Miami, FL.
   Google Scholar
• Stahl A, Stumpp MT, Schlegel A, et al. Highly potent VEGF-A-antagonistic DARPins as anti-angiogenic agents for topical and intravitreal applications. Angiogenesis. 2013 Jan;16(1):101–111.
   PubMed Web of Science ®Google Scholar
• Evaluation of AGN-150998 in exudative age-related macular degeneration (AMD); cited 2016 Mar 17. Available from: https://clinicaltrials.gov/ct2/show/NCT01397409.
   Google Scholar
• Campochiaro PA, Channa R, Berger BB, et al. Treatment of diabetic macular edema with a designed ankyrin repeat protein that binds vascular endothelial growth factor: a phase I/II study. Am J Ophthalmol. 2013 Apr 4;155:697–704, 704.e1-2. Epub 2012 Dec 4. doi:10.1016/j.ajo.2012.09.032.
   PubMed Web of Science ®Google Scholar
• Tolentino MJ, Dennrick A, John E, et al. Drugs in Phase II clinical trials for the treatment of age-related macular degeneration. Expert Opin Investig Drugs. 2015 Feb;24(2):183–199.
   PubMed Web of Science ®Google Scholar
• Igarashi T, Miyake K, Masuda I, et al. Adeno-associated vector (type-8)-mediated expression of soluble Flt-1 efficiently inhibits neovascularization in a murine choroidal neovascularization model. Hym Gene Ther. 2010;21(5):631–637.
   PubMed Web of Science ®Google Scholar
• Choudhury P, Chen W, Hunt RC. Production of platelet-derived growth factor by interleukin-1 beta and transforming growth factor-beta-stimulated retinal pigment epithelial cells leads to contraction of collagen gels. Invest Ophthal Vis Sci. 1997;38(5):824–833.
   PubMed Web of Science ®Google Scholar
• Jo N, Mailhos C, Ju M, et al. Inhibition of platelet-derived growth factor B signaling enhances the efficacy of antivascular endothelial growth factor therapy in multiple models of ocular neovascularization. Am J Pathol. 2006;168(6):2036–2053.
   PubMed Web of Science ®Google Scholar
• Dugel P. Phase 2b clinical trial of Fovista anti-PDGF therapy (1.5 mg) in patients with neovascular age-related macular degeneration (wet AMD). Retina subspecialty Day the American Academy of Ophthalmology Annual Meeting (AAO); 2012 Nov 10; Chicago.
   Google Scholar
• McLaughlin MM, Paglione MG, Slakter J, et al. Initial exploration of oral pazopanib in healthy participants and patients with age-related macular degeneration. JAMA Ophthalmol. 2013;131(12):1595–1601.
   PubMed Web of Science ®Google Scholar
• Thakur A, Scheinman RI, Rao VR, et al. Pazopanib, a multitargeted tyrosine kinase inhibitor, reduces diabetic retinal vascular leukostasis and leakage. Microvasc Res. 2011;82(3):346–350.
   PubMed Web of Science ®Google Scholar
• Danis R, McLaughlin MM, Tolentino M, et al. Pazopanib eye drops: a randomized trialin neovascular age-related macular degeneration. Br J Ophthalmol. 2014;98(2):172–178.
   PubMed Web of Science ®Google Scholar
• Kumar R, Knick VB, Rudolph SK, et al. Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Mol Cancer Ther. 2007;6(7):2012–2021.
   PubMed Web of Science ®Google Scholar
• Kernt M, Thiele S, Neubaer AS, et al. Inhibitory activity of ranibizumab, sorafenib, and pazopanib on light-induced overexpression of platelet-derived growth factor A and the vascular endothelial growth factor a receptors 1 and 2 and neuropilin 1 and 2. Retina. 2012;32(8):1652–1663.
   PubMed Web of Science ®Google Scholar
• Csaky KG, Dugel PU, Pierce AJ, et al. Clinical evaluation of pazopanib eye drops versus ranibizumab intravitreal injections in subjects with neovascular age-related macular degeneration. Ophthalmology. 2015 Mar;122(3):579–588.
   PubMed Web of Science ®Google Scholar
• Wilhelm SM, Dumas J, Adnane L, et al. Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer. 2011;129(1):245–255.
   PubMed Web of Science ®Google Scholar
• Pecen PE, Kaiser PK. Current phase 1/2 research for neovascular age-related macular degeneration. Curr Opin Ophthalmol. 2015 May;26(3):188–193.
   PubMed Web of Science ®Google Scholar
• Zhao C, Vollrath D. mTOR pathway activation in age-related retinal disease. Aging (Albany NY). 2011 Apr;3(4):346–347.
   PubMedGoogle Scholar
• Nguyen QD, Schachar RA, Nduaka CI, et al. Evaluation of the siRNA PF-04523655 versus ranibizumab for the treatment of neovascular age-related macular degeneration (MONET study). Ophthalmology. 2012 Sep; 119(9):1867–1873.
   PubMed Web of Science ®Google Scholar
• Zhao C, Yasumura D, Li X, et al. mTOR-mediated dedifferentiation of the retinal pigment epithelium initiates photoreceptor degeneration in mice. J Clin Invest. 2011;121:369–383.
   PubMed Web of Science ®Google Scholar
• Caballero S, Swaney J, Moreno K, et al. Anti-sphingosine-1-phosphate monoclonal antibodies inhibit angiogenesis and sub-retinal fibrosis in a murine model of laser-induced choroidal neovascularization. Exp Eye Res. 2009;88(3):367–377.
   PubMed Web of Science ®Google Scholar
• Xie B, Shen J, Dong A, et al. Blockade of sphingosine-1-phosphate reduces macrophage influx and retinal and choroidal neovascularization. J Cell Physiol. 2009;218(1):192–198.
   PubMed Web of Science ®Google Scholar
• Sabbadini RA. Sphingosine-1-phosphate antibodies as potential agents in the treatment of cancer and age-related macular degeneration. Br J Pharmacol. 2011;162(6):1225–1238.
   PubMed Web of Science ®Google Scholar
• Emerson MC, Lauer AK. Current and emerging therapies for the treatment of age-related macular degeneration. Clin Ophthalmol. 2008 Jun;2(2):377–388.
   PubMedGoogle Scholar
• Auricchio A, Behling KC, Maguire AM, et al. Inhibition of retinal neovascularization by intraocular viral-mediated delivery of anti-angiogenic agents. Mol Ther. 2002;6(4):490–494.
   PubMed Web of Science ®Google Scholar
• Binley K, Widdowson PS, Kelleher M, et al. Safety and biodistribution of an equine infectious anemia virus-based gene therapy, RetinoStat(®), for age-related macular degeneration. Hum Gene Ther. 2012 Sep;23(9):980–991.
   PubMed Web of Science ®Google Scholar
• Camardo J. The Rapamune era of immunosuppression 2003: the journey from the laboratory to clinical transplantation. Transplant Proc. 2003;35:18S–24S.
   PubMed Web of Science ®Google Scholar
• Phillips BN, Wroblewski KJ. A retrospective review of oral low-dose sirolimus (rapamycin) for the treatment of active uveitis. J Ophthalmic Inflamm Infect. 2010;1:29–34.
   PubMedGoogle Scholar
• Shanmuganathan VA, Casely EM, Raj D, et al. The efficacy of sirolimus in the treatment of patients with refractory uveitis. Br J Ophthalmol. 2005;89:666–669.
   PubMed Web of Science ®Google Scholar
• Nussenblatt RB, Byrnes G, Sen HN, et al. A randomized pilot study of systemic immunosuppression in the treatment of age-related macular degeneration with choroidal neovascularization. Retina. 2010;30:1579–1587.
   PubMed Web of Science ®Google Scholar
• Brown EJ, Albers MW, Shin TB, et al. A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature. 1994;369:756–758.
   PubMed Web of Science ®Google Scholar
• Sabatini DM, Erdjument-Bromage H, Lui M, et al. RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs. Cell. 1994;78:35–43.
   PubMed Web of Science ®Google Scholar
• Mudumba S, Bezwada P, Takanaga H, et al. Tolerability and pharmacokinetics of intravitreal sirolimus. J Ocul Pharmacol Ther. 2012;28:507–514.
   PubMed Web of Science ®Google Scholar
• Wong WT, Dresner S, Forooghian F, et al. Treatment of geographic atrophy with subconjunctival sirolimus: results of a phase I/II clinical trial.” Investigative opthalmology & visual science invest. Ophthalmol Vis Sci. 2013;54(4):2941. Web.
   PubMed Web of Science ®Google Scholar
• Krishnan L, Krishnan EC, Jewell WR. Immediate effect of irradiation on microvasculature. Int J Radiat Oncol Biol Phys. 1988;15:147–150.
   PubMed Web of Science ®Google Scholar
• Chakravarthy U, Gardiner TA, Archer DB, et al. A light microscopic and autoradiographic study of non-irradiated and irradiated ocular wounds. Curr Eye Res. 1989;8:337–348.
   PubMed Web of Science ®Google Scholar
• Sivagnanavel V, Evans JR, Ockrim Z, et al. Radiotherapy for neovascular age-related macular degeneration. Cochrane Database Syst Rev. 2004;4:CD004004.
   PubMedGoogle Scholar
• Finger PT, Gelman YP, Berson AM, et al. Palladium-103 plaque radiation therapy for macular degeneration: results of a 7 year study. Br J Ophthalmol. 2003;87:1497–1503.
   PubMed Web of Science ®Google Scholar
• Adams JA, Paiva KL, Munzenrider JE, et al. Proton beam therapy for age-related macular degeneration: development of a standard plan. Med Dosim. 1999;24:233–238.
   PubMedGoogle Scholar
• Zambarakji HJ, Lane AM, Ezra E, et al. Proton beam irradiation for neovascular age-related macular degeneration. Ophthalmology. 2006;113:2012–2019.
   PubMed Web of Science ®Google Scholar
• Gertner M, Chell E, Pan KH, et al. Stereotactic targeting and dose verification for age-related macular degeneration. Med Phys. 2010;37:600–606.
   PubMed Web of Science ®Google Scholar
• Avila MP, Farah ME, Santos A, et al. Twelve-month short-term safety and visual-acuity results from a multicentre prospective study of epiretinal strontium-90 brachytherapy with bevacizumab for the treatment of subfoveal choroidal neovascularisation secondary to age-related macular degeneration. Br J Ophthalmol. 2009;93:305–309.
   PubMed Web of Science ®Google Scholar
• Avila MP, Farah ME, Santos A, et al. Twelve-month safety and visual acuity results from a feasibility study of intraocular, epiretinal radiation therapy for the treatment of subfoveal CNV secondary to AMD. Retina. 2009;29:157–169.
   PubMed Web of Science ®Google Scholar
• Silva RA, Moshfeghi AA, Kaiser PK, et al. Radiation treatment for age-related macular degeneration. Semin Ophthalmol. 2011;26:121–130.
   PubMed Web of Science ®Google Scholar
• Jackson TL, Chakravarthy U, Kaiser PK, et al. Stereotactic radiotherapy for neovascular age-related macular degeneration: 52-week safety and efficacy results of the INTREPID study. Ophthalmology. 2013;120:1893–1900.
   PubMed Web of Science ®Google Scholar
• Petrarca R, Dugel PU, Nau J, et al. Macular epiretinal brachytherapy in treated age-related macular degeneration (MERITAGE): month 12 optical coherence tomography and fluorescein angiography. Ophthalmology. 2013;120:328–333.
   PubMed Web of Science ®Google Scholar
• Petrarca R, Dugel PU, Bennett M, et al. Macular epiretinal brachytherapy in treated age-related macular degeneration (MERITAGE): month 24 safety and efficacy results. Retina. 2014;34:874–879.
   PubMedGoogle Scholar
• Dugel PU, Petrarca R, Bennett M, et al. Macular epiretinal brachytherapy in treated age-related macular degeneration: MERITAGE study: twelve-month safety and efficacy results. Ophthalmology. 2012;119(7):1425–1431.
   Google Scholar
• Petrarca R, Dugel PU, Bennett M, et al. Macular epiretinal brachytherapy in treated age-related macular degeneration (MERITAGE): month 24 safety and efficacy results. Retina. 2014 May;34(5):874–879.
   PubMedGoogle Scholar
• Dugel PU, Bebchuk JD, Nau J, et al. Epimacular brachytherapy for neovascular age-related macular degeneration: a randomized, controlled trial (CABERNET). Ophthalmol. 2013 Feb; 120(2):317–327.
   PubMed Web of Science ®Google Scholar
• Jackson TL, Dugel PU, Bebchuk JD, et al. Epimacular brachytherapy for neovascular age-related macular degeneration (CABERNET): fluorescein angiography and optical coherence tomography. Ophthalmology. 2013 Aug; 120(8):1597–1603.
   PubMed Web of Science ®Google Scholar
• Lim JI, Niec M, Wong V. One year results of a phase 1 study of the safety and tolerability of combination therapy using sustained release intravitreal triamcinolone acetonide and ranibizumab for subfoveal neovascular AMD. Br J Ophthalmol. 2015 May;99(5):618–623.
   PubMed Web of Science ®Google Scholar
• Becerra EM, Morescalchi F, Gandolfo F, et al. Clinical evidence of intravitreal triamcinolone acetonide in the management of age-related macular degeneration. Curr Drug Targets. 2011;12:149–172.
   PubMed Web of Science ®Google Scholar
• Veritti D, Sarao V, Lanzetta P. Bevacizumab and triamcinolone acetonide for choroidal neovascularization due to age-related macular degeneration unresponsive to antivascular endothelial growth factors. J Ocul Pharmacol Ther. 2013;29:437–441.
   PubMed Web of Science ®Google Scholar
• Freund KB, Mrejen S, Gallego-Pinazo R. An update on the pharmacotherapy of neovascular age-related macular degeneration. Expert Opin Pharmacother. 2013;14:1017–1028.
   PubMed Web of Science ®Google Scholar
• Augustin AJ, Puls S, Offermann I. Triple therapy for choroidal neovascularization due to age-related macular degeneration: verteporfin PDT, bevacizumab, and dexamethasone. Retina. 2007 Feb;27(2):133–140.
   PubMed Web of Science ®Google Scholar
• Jaffe GJ, Eliott D, Wells JA, et al. 1 Study of intravitreous E10030 in combination with ranibizumab in neovascular age-related macular degeneration. Ophthalmology. 2016 Jan;123(1):78–85.
   PubMed Web of Science ®Google Scholar
• Myers AL, Williams RF, Ng CY, et al. Bevacizumab-induced tumor vessel remodeling in rhabdomyosarcoma xenografts increases the effectiveness of adjuvant ionizing radiation. J Pediatr Surg. 2010;45:1080–1085.
   PubMed Web of Science ®Google Scholar
• Willett CG, Kozin SV, Duda DG, et al. Combined vascular endothelial growth factor-targeted therapy and radiotherapy for rectal cancer: theory and clinical practice. Semin Oncol. 2006;33(5 suppl 10):S35–40.
   PubMed Web of Science ®Google Scholar
• Nieder C, Wiedenmann N, Andratschke N, et al. Current status of angiogenesis inhibitors combined with radiation therapy. Cancer Treat Rev. 2006;32:348–364.
   PubMed Web of Science ®Google Scholar
• Liu Q, Xu Q, Zheng VW, et al. Multi-task learning for cross-platform siRNA efficacy prediction: an in-silico study. BMC Bioinformatics. 2010;11:181.
   PubMed Web of Science ®Google Scholar
• Garba AO, Mousa SA, Garba AO. Bevasiranib for the treatment of wet, age-related macular degeneration. Ophthalmol Eye Dis. 2010:2:75–83.
   PubMedGoogle Scholar
• Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group, Maguire MG, Martin DF, et al. Five-year outcomes with anti-vascular endothelial growth factor treatment of neovascular age-related macular degeneration: the comparison of age-related macular degeneration treatments trials. ophthalmology. 2016 Apr 20. pii:S0161-6420(16)30092-6. doi:10.1016/j.ophtha.2016.03.045.
   Web of Science ®Google Scholar
• Ying GS, Huang J, Maguire MG, et al. Baseline predictors for one-year visual outcomes with ranibizumab or bevacizumab for neovascular age-related macular degeneration. Ophthalmology. 2013 Jan;120(1):122–129.
   PubMed Web of Science ®Google Scholar